Drug intelligence / Profile preview

AVX70120

Development stage: Phase 1
Lead developer: AstriVax Therapeutics
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

AVX70120 is a prophylactic vaccine candidate developed by AstriVax for the prevention of yellow fever. It is built on the company's proprietary Launch-iT platform, which utilizes a thermostable, plug-and-play technology derived from research at the KU Leuven Rega Institute. The platform is designed to create vaccines that do not require a cold chain and provide long-lasting protection. AVX70120 is currently being evaluated in a Phase 1 clinical trial to assess its safety, reactogenicity, and immunogenicity in healthy adults.

Other names: AVX70120AVX-70120AVX 70120

Beyond the preview

Go deeper on AVX70120.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVX70120.

Explore the full profile